Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Alcobra Hopes To Continue Development In Fragile X On Quality Of Life Findings

This article was originally published in The Pink Sheet Daily

Executive Summary

Israeli firm contends that secondary endpoints address factors that matter most to patients, clinicians and caregivers, even though its metadoxine failed on the primary efficacy measure.

Advertisement

Related Content

Alcobra’s Pipeline In A Pill Aims To Capture The ADHD Market And More

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register